• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Cannabis Market
Cannabis News
Cannabis Stocks
  • Cannabis Market
  • Cannabis News
  • Cannabis Stocks

Revive Therapeutics Gets Nexalogy to Build AI Element for Cannabis Blockchain Program

Bryan Mc Govern
Nov. 27, 2017 09:37AM PST
Cannabis Investing News

Revive Therapeutics announced it has tapped the services of Datametrex AI Limited’s subsidiary Nexalogy Environics to develop the AI component in Revive’s proprietary patient-focused program enabled by blockchain technology dedicated to the medical cannabis industry.

Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) announced it has tapped the services of Datametrex AI Limited’s (TSXV:DM) subsidiary Nexalogy Environics to develop the AI component in Revive’s proprietary patient-focused program enabled by blockchain technology dedicated to the medical cannabis industry.
As quoted in the press release:

“We are excited to work with Revive to develop their proprietary patient-focused program for their commercialization efforts in the medical cannabis sector. We believe there is a massive opportunity in developing unique technology solutions for all constituents in the medical cannabis sector and their proposed medical cannabis patient-focused platform that includes an AI component is one example of the many sector opportunities Nexalogy can target,” said Andrew Ryu, Chairman and Chief Executive Officer of the Company.
Under the terms of the Agreement Datametrex will receive an upfront license fee along with monthly fees. Datametrex will grant to Revive a non-transferable, non-sub-licensable, and non-exclusive licence to use Nexalogy’s proprietary AI solution, solely to obtain insights and intelligence of medical cannabis user experience expressed on social media.  The duration of the Agreement is for six months and the Agreement may be extended at the request and acceptance by both Datametrex and Revive (the “Parties”).

Click here to read the full press release.

Source: globenewswire.com

revive therapeutics
The Conversation (0)

Go Deeper

AI Powered
A colorful brain illustrating brain on pyschedelics.

Psychedelics Stocks to Watch

Person touching a cannabis plant; Australia map in flag colours.

ASX Cannabis Stocks: 10 Biggest Companies in 2025

Latest News

More News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Cannabis Investing News Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES